DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors.
Harris, P.A., King, B.W., Bandyopadhyay, D., Berger, S.B., Campobasso, N., Capriotti, C.A., Cox, J.A., Dare, L., Dong, X., Finger, J.N., Grady, L.C., Hoffman, S.J., Jeong, J.U., Kang, J., Kasparcova, V., Lakdawala, A.S., Lehr, R., McNulty, D.E., Nagilla, R., Ouellette, M.T., Pao, C.S., Rendina, A.R., Schaeffer, M.C., Summerfield, J.D., Swift, B.A., Totoritis, R.D., Ward, P., Zhang, A., Zhang, D., Marquis, R.W., Bertin, J., Gough, P.J.(2016) J Med Chem 59: 2163-2178
- PubMed: 26854747 
- DOI: 10.1021/acs.jmedchem.5b01898
- Primary Citation of Related Structures:  
5HX6 - PubMed Abstract: 
The recent discovery of the role of receptor interacting protein 1 (RIP1) kinase in tumor necrosis factor (TNF)-mediated inflammation has led to its emergence as a highly promising target for the treatment of multiple inflammatory diseases. We screened RIP1 against GSK's DNA-encoded small-molecule libraries and identified a novel highly potent benzoxazepinone inhibitor series ...